A new version of EudroVigillance, the European information system of Suspected Adverse Reactions to medicines that are authorized or being studied in clinical trials in the European Economic Area (EEA) is available.
The new system makes it easier for marketing authorization holders and sponsors of clinical trials to report Suspected Adverse reactions and allows for better analysis of this information for the benefit of patient safety in Europe.
Posted by Dr. Tim Sandle
